SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 14th, 2018 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 14, 2018, between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTUREImmune Pharmaceuticals Inc • May 14th, 2018 • Pharmaceutical preparations • New York
THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued Original Issue Discount Convertible Debentures of Immune Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 550 Sylvan Avenue, Suite 101. Englewood Cliffs, NJ. 07632, designated as its Original Issue Discount Convertible Debenture due on the Maturity Date (as defined below) (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
